Galectin Therapeutics (GALT)

• Market cap: $65.3M
• 1 day: -48.00%
• 5 days: -52.73%
• 1 month: -63.12%
• 3 months: -62.45%
• 6 months: -57.02%
• Year to date: -40.23%
• 1 year: -39.18%
• 5 years: -63.89%
• 10 years: -70.70%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 14

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

21% more capital invested

Capital invested by funds: $22.1M [Q2] → $26.8M (+$4.66M) [Q3]

8% more funds holding

Funds holding: 73 [Q2] → 79 (+6) [Q3]

0% more ownership

Funds ownership: 15.68% [Q2] → 15.68% (+0%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 19

42% less call options, than puts

Call options by funds: $3.18M | Put options by funds: $5.45M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $11 958% upside
• Avg. target: $11 958% upside
• High target: $11 958% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 54% 1-year accuracy 79 / 146 met price target

958% upside $11

Buy Reiterated

15 Nov 2024